Consequently, the distributionally robust quadratic cost constraint can be decomposed into ... Then, the distributionally robust cost constraint in PVF-AADRO is handled by dual vertex generation, and ...

This algorithm has quadratic run time so it can be slow with very large profiles ... with many edges meeting at each polygon vertex. The result is an alternation of flat triangular faces with conical ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

Reports Q4 revenue $2.91B, consensus $2.78B. “2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another ...

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...